Kite Pharma (KITE) Tops Q2 EPS by 30c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/11/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mailGet Alerts KITE Hot Sheet
Join SI Premium – FREE
Kite Pharma (NASDAQ: KITE) reported Q2 EPS of ($0.91), $0.30 better than the analyst estimate of ($1.21). Revenue for the quarter came in at $4.8 million versus the consensus estimate of $4.86 million.
For earnings history and earnings-related data on Kite Pharma (KITE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Top AI Semiconductor Stocks According to Stifel Analysis
- Helen of Troy (HELE) PT Raised to $29 at UBS on Q2 Beat
- HIMS jumps 7% on peptide tailwind but Citi sees 17% downside from here
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
